AtriCureNASDAQ: ATRC

AtriCure, Inc. (NASDAQ: ATRC) Q1 2024 Earnings Conference Call on May 1, 2024 at 4:30 PM ET with Marissa Bych, Mike Carrel, and Angie Wirick participating. Conference call participants include Robbie Marcus, William Plovanic, Marie Thibault, Danielle Antalffy, Daniel Stauder, Mike Matson, Suraj Kalia. The operator welcomes everyone to the call which is being recorded for replay.

The financial results for AtriCure (ATRC) for the quarter ending in March 2024 provide a glimpse into the company's performance, but it could be beneficial to analyze certain key metrics in comparison to analyst predictions and the previous year's figures.

AtriCure (ATRC) reported a quarterly loss of $0.25 per share, missing the Zacks Consensus Estimate of a loss of $0.21. This is higher than the loss of $0.23 per share reported in the same quarter last year.

AtriCure (ATRC) introduces the cryoSPHERE+ cryoablation probe to shorten freeze times and assist with postoperative pain control.

AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AtriCure (ATRC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.09 per share a year ago.

AtriCure has seen solid revenue growth but needs more operating leverage to improve its bottom line. The company's shares have experienced a meaningful pullback from their highs in June. Despite continued losses, AtriCure's progress on the margin front and expected sales growth in 2024 make its sales multiple compelling.

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).